18 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 14 Phase 1, 8 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 2 | 8 | Completed 3, Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow relacorilant: new trials by email Literature Review of relacorilant trials Research Report on relacorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Relacorilant, Nab-paclitaxel, Gemcitabine - Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | Corcept Therapeutics | 80 | 2026-01-27 | 2026-09-25 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Corcept Therapeutics | 270 | 2025-04-11 | 2026-07-16 |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Relacorilant, Enzalutamide, Placebo (Sugar Pill) - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Chicago | 90 | 2025-01-06 | 2026-08-31 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2 - Ovarian Neoplasm, Fallopian Tube Neoplasms | Phase 3 | Active not recruiting | Corcept Therapeutics | 381 | 2022-06-29 | 2026-09-25 |
| Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants Dabigatran Etexilate, Relacorilant - Cushing Syndrome, Neoplasms | Phase 1 | Completed | Corcept Therapeutics | 30 | 2022-05-25 | 2023-02-09 |
| T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers Relacorilant, Placebo to relacorilant, Moxifloxacin - Healthy | Phase 1 | Completed | Corcept Therapeutics | 36 | 2021-01-22 | 2021-09-14 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-09-19 | 2023-10-23 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Relacorilant, Placebo - Hypercortisolism | Phase 3 | Completed | Corcept Therapeutics | 137 | 2020-07-27 | 2025-09-04 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Corcept Therapeutics | 43 | 2020-06-30 | 2023-11-18 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant Relacorilant - Hepatic Impairment | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-01-06 | 2023-10-23 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Relacorilant, Nab-paclitaxel - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma | Phase 2 | Completed | Corcept Therapeutics | 178 | 2019-04-05 | 2025-10-07 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Enzalutamide, Relacorilant - Prostate Cancer | Phase 1 | Completed | University of Chicago | 42 | 2018-10-23 | 2026-03-31 |
| A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules) - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-05-24 | 2018-09-07 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-10-09 |
| Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites Relacorilant 350mg, Itraconazole, Relacorilant 300mg - Healthy | Phase 1 | Completed | Corcept Therapeutics | 52 | 2018-04-10 | 2020-03-24 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride - Healthy | Phase 1 | Completed | Corcept Therapeutics | 27 | 2018-03-06 | 2018-05-17 |
| Relacorilant Food Effect Study in Healthy Subjects Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast - Healthy, Food-drug Interaction | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-01-16 | 2018-05-17 |
Showing 20 of 25. Sign in to see all of them.
Cushing Syndrome (6) · ACTH Syndrome, Ectopic (5) · Diabetes Mellitus, Type 2 (5) · Hypertension (5) · Adrenal Cortex Neoplasms (3) · Adrenocortical Carcinoma (3) · Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Pituitary ACTH Hypersecretion (3) · Neoplasms (2) · Pancreatic Neoplasms (2) · Peritoneal Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Adrenal Gland Diseases (1)
Corcept Therapeutics (22) · University of Chicago (2) · ARCAGY/ GINECO GROUP (1)
United States (23) · Italy (7) · Spain (6) · Poland (5) · Canada (4) · Germany (4) · Israel (4) · Austria (3) · Belgium (3) · France (3) · Netherlands (3) · Romania (3) · United Kingdom (3) · Bulgaria (2) · Hungary (2)
Joseph Custodio, PhD (3) · Andreas G Moraitis, MD (2) · Andreas Moraitis, MD (2) · Joseph Custodio (2) · Kirsteen Donaldson, FFPM,DM,FRCP (2) · Russell Szmulewitz, MD (2) · Ada Lee, MD (1) · Adrian Jubb, MBChB, PhD, FRCPath (1) · Andreas Moraitis (1) · Danny Nguyen (1) · Danny Nguyen, MD (1) · Hazel Hunt (1) · John McNally (1)
PMID 35058882, PMID 37364223, PMID 34335465, PMID 35110415, PMID 39032926, PMID 40051286, PMID 40473448, PMID 41730814, PMID 41974149
2014 (1), P50CA180995 (1)